DrugDrug NameDrug Indication
DB00840Hydroxypropyl celluloseUsed to relieve dryness and irritation caused by reduced tear flow that occurs in certain eye diseases (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis, and as a lubricant for artificial eyes.
DB00677IsoflurophateFor use in the eye to treat certain types of glaucoma and other eye conditions, such as accommodative esotropia.
DB00751EpinastineFor the prevention of itching associated with allergic conjunctivitis.
DB00885PemirolastFor the prevention of itching of the eyes caused by allergies such as hay fever, and allergic conjunctivitis
DB00964ApraclonidineFor prevention or reduction of intraoperative and postoperative increases in intraocular pressure (IOP) before and after ocular laser surgery when used prophylactically. Also used as a short-term adjunctive therapy in patients with open-angle glaucoma who are on maximally tolerated medical therapy requiring additional IOP reduction.
DB01144DiclofenamideFor adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure
DB01194BrinzolamideFor the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
DB01270RanibizumabFor the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
DB00847CysteamineGiven intravenously or orally to treat radiation sickness. The bitartrate salts (Cystagon® and Procysbi) have been used for the oral treatment of nephropathic cystinosis and cystinurea. The hydrochloride salt (Cystaran™) is indicated for the treatment of corneal cystine crystal accumulation in cystinosis patients.
DB08885AfliberceptThe opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.
DB08888OcriplasminOcriplasmin is a proteolytic enzyme indicated for the treatment for symptomatic vitreomacular adhesion.
DB08819TafluprostTafluprost is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
DB00287TravoprostTravoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension [F3061, F3064, L5146]. Travoprost is also currently indicated for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma [L5146].
DB00298DapiprazoleUsed in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents used in certain eye examinations.
DB00449DipivefrinDipivefrin is a prodrug which is used as initial therapy for the control of intraocular pressure in chronic open-angle glaucoma.
DrugDrug NameTargetType
DB00677IsoflurophateSerum albumincarrier
DB00751EpinastineHistamine H1 receptortarget
DB00751EpinastineHistamine H2 receptortarget
DB00751EpinastineAlpha-1A adrenergic receptortarget
DB00751EpinastineAlpha-2A adrenergic receptortarget
DB00751Epinastine5-hydroxytryptamine receptor 2Atarget
DB00751Epinastine5-hydroxytryptamine receptor 7target
DB00751EpinastineMultidrug resistance protein 1transporter
DB00751EpinastineCytochrome P450 2B6enzyme
DB00751EpinastineCytochrome P450 2D6enzyme
DB00751EpinastineCytochrome P450 3A4enzyme
DB00964ApraclonidineAlpha-2A adrenergic receptortarget
DB00964ApraclonidineAlpha-1A adrenergic receptortarget
DB00964ApraclonidineAlpha-2B adrenergic receptortarget
DB01144DiclofenamideCarbonic anhydrase 1target
DB01144DiclofenamideCarbonic anhydrase 4target
DB01144DiclofenamideCarbonic anhydrase 2target
DB01144DiclofenamideCarbonic anhydrase 7target
DB01144DiclofenamideCarbonic anhydrase 3target
DB01194BrinzolamideCarbonic anhydrase 1target
DB01194BrinzolamideCarbonic anhydrase 2target
DB01194BrinzolamideCytochrome P450 3A4enzyme
DB01194BrinzolamideCarbonic anhydrase 5A, mitochondrialtarget
DB01194BrinzolamideCarbonic anhydrase 4target
DB01194BrinzolamideCarbonic anhydrase 3target
DB01270RanibizumabVascular endothelial growth factor Atarget
DB00847CysteamineNeuropeptide Y receptor type 2target
DB08885AfliberceptVascular endothelial growth factor Atarget
DB08885AfliberceptPlacenta growth factortarget
DB08885AfliberceptVascular endothelial growth factor Btarget
DB08819TafluprostProstaglandin F2-alpha receptortarget
DB08819TafluprostProstaglandin G/H synthase 2enzyme
DB00287TravoprostProstaglandin F2-alpha receptortarget
DB00298DapiprazoleAlpha-1A adrenergic receptortarget
DB00298DapiprazoleAlpha-1D adrenergic receptortarget
DB00298DapiprazoleAlpha-1B adrenergic receptortarget
DB00449DipivefrinAlpha-2A adrenergic receptortarget
DB00449DipivefrinBeta-2 adrenergic receptortarget
DB00449DipivefrinAlpha-1A adrenergic receptortarget